Trial · NCT00923091
Participant flow195
How many started, completed or left each group, period by period.
1 to 20 of 195
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5mg | 335 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 336 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 336 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 336 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan/Amlodipine/Hydrochlorothiazide(HCT) 40mg/10mg/25mg | 336 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan(OM)20mg/Amlodipine (AML)5mg | 337 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan/Amlodipine 40mg/5mg | 337 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | Olmesartan/Amlodipine 40mg/10mg | 336 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | OM/AML/HCT 40/5/12.5mg Responder Continued on 40/5/12.5 mg | 0 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | OM/AML/HCT 40/5/12.5mg Non Responder Randomized to 40/5/12.5mg | 0 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | OM/AML/HCT 40/5/12.5mg Non Responder Randomized to 40/5/25mg | 0 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | OM/AML/HCT 20/5/12.5mg NonResponder Up Titrated to 40/5/12.5mg | 0 | |
| PeriodI-II (Randomized, Double-Blind) | STARTED | 20/5/12.5mg Responder Continued on 20/5/12.5 mg | 0 | |
| PeriodI-II (Randomized, Double-Blind) | COMPLETED | Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5mg | 319 | |
| PeriodI-II (Randomized, Double-Blind) | COMPLETED | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 325 | |
| PeriodI-II (Randomized, Double-Blind) | COMPLETED | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 323 | |
| PeriodI-II (Randomized, Double-Blind) | COMPLETED | Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 309 | |
| PeriodI-II (Randomized, Double-Blind) | COMPLETED | Olmesartan/Amlodipine/Hydrochlorothiazide(HCT) 40mg/10mg/25mg | 315 | |
| PeriodI-II (Randomized, Double-Blind) | COMPLETED | Olmesartan(OM)20mg/Amlodipine (AML)5mg | 322 | |
| PeriodI-II (Randomized, Double-Blind) | COMPLETED | Olmesartan/Amlodipine 40mg/5mg | 319 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00923091/flow